Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.

Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.

Johnson & Johnson’s blockbuster $2.2 billion Risperdal settlement resolves off-label marketing claims over the anti-psychotic drug, but it will have little effect on product liability litigation in Pennsylvania, where plaintiffs attorneys expect ...read more

  • Tags: